Shah S - Search Results

1

The development of T-cell malignancies in patients with pre-existing myeloproliferative neoplasms: a report of three cases.

Burns EA, Anand K, Chung B, Shah S, Randhawa JK, Pingali SR. Burns EA, et al. Among authors: shah s. Ecancermedicalscience. 2020 Feb 17;14:1011. doi: 10.3332/ecancer.2020.1011. eCollection 2020. Ecancermedicalscience. 2020. PMID: 32256694 Free PMC article.

2

Multiple myeloma with concurrent immune thrombocytopenic purpura.

Sarfraz H, Anand K, Liu S, Shah S. Sarfraz H, et al. Among authors: shah s. Ecancermedicalscience. 2020 Feb 20;14:1012. doi: 10.3332/ecancer.2020.1012. eCollection 2020. Ecancermedicalscience. 2020. PMID: 32256695 Free PMC article.

3

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.

Gentille C, Sarfraz H, Joshi J, Randhawa J, Shah S, Pingali SR. Gentille C, et al. Among authors: shah s. Cancer Rep (Hoboken). 2022 Jul;5(7):e1581. doi: 10.1002/cnr2.1581. Epub 2022 Mar 8. Cancer Rep (Hoboken). 2022. PMID: 35263030 Free PMC article.

4

Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry.

Burns EA, Sanchez CG, Mathur S, Guerrero C, Muhsen IN, Sarfraz H, Hu CA, Tang CA, Shah SS, Tremont IW, Teh B, Ganguly S, Pingali SRK. Burns EA, et al. Among authors: shah ss. Ann Hematol. 2023 May;102(5):1111-1120. doi: 10.1007/s00277-023-05140-6. Epub 2023 Mar 16. Ann Hematol. 2023. PMID: 36922432

5

Long-term outcomes in patients with Burkitt lymphoma older than 65 years: an analysis of the Texas Cancer Registry.

Burns EA, Wilson JJ, Mathur S, Kieser R, Gong Z, Hu CA, Tang CA, Petkova J, Yuen C, Mai H, Shah S, Rice L, Ganguly S, Pingali SR. Burns EA, et al. Among authors: shah s. Ann Hematol. 2023 Oct;102(10):2753-2763. doi: 10.1007/s00277-023-05328-w. Epub 2023 Jul 8. Ann Hematol. 2023. PMID: 37422592

6

Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia.

Shao J, Shah S, Ganguly S, Zu Y, He C, Li Z. Shao J, et al. Among authors: shah s. Clin Epigenetics. 2023 Aug 24;15(1):134. doi: 10.1186/s13148-023-01547-0. Clin Epigenetics. 2023. PMID: 37620919 Free PMC article.

7

Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia.

Shao J, Wang S, West-Szymanski D, Karpus J, Shah S, Ganguly S, Smith J, Zu Y, He C, Li Z. Shao J, et al. Among authors: shah s. Sci Rep. 2022 Jul 20;12(1):12410. doi: 10.1038/s41598-022-16685-3. Sci Rep. 2022. PMID: 35859008 Free PMC article.

8

Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine.

Shao J, Shah S, Ganguly S, Zu Y, He C, Li Z. Shao J, et al. Among authors: shah s. Genes (Basel). 2023 May 28;14(6):1180. doi: 10.3390/genes14061180. Genes (Basel). 2023. PMID: 37372359 Free PMC article.

9

Treatment of primary cardiac diffuse large B-cell lymphoma involving the coronary sinus with R-EPOCH: a case report and literature review.

Rezvani A, Shah S. Rezvani A, et al. Among authors: shah s. Ann Hematol. 2024 Jul;103(7):2557-2560. doi: 10.1007/s00277-024-05793-x. Epub 2024 May 15. Ann Hematol. 2024. PMID: 38748259 Review.

10

Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement.

Mooneyham J, Gentille C, Barbieri A, Shah S. Mooneyham J, et al. Among authors: shah s. BMJ Case Rep. 2020 Sep 7;13(9):e235412. doi: 10.1136/bcr-2020-235412. BMJ Case Rep. 2020. PMID: 32900727 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,483 results

Search Page

Filters